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The term GMP was introduced to regulate 
manufacturing and packaging operations in the 
pharmaceutical industry. The Medicine Inspector of the 
Department of Health and Social Security of England, in 
consultation with other interested bodies compiled the 
guide to GMP also known as the Orange Guide. The 
first edition of the guide was published in 1971, the 
manufacturing of drug carried out under the Medicines 
Act. It was a relatively light volume of20 pages, and 
was reissue third impression in1972, with the addition of 
a 2-page appendix on sterile medicinal products. The 
color of its cover, it known as the Orange Guide. The 
second edition (52 pages, including five appendices) 
was published in 1977. The third edition (110 pages, 
five appendices) was published in 1983
1
. 
The Medicines and Healthcare products Regulatory 
Agency (MHRA) has published new edition of the 
Orange Guide in 2007. In United States, the first GMP 
regulations were issued in1963 and described the GMP 
to be followed in the manufacture, packaging, and 
storage of finished pharmaceutical products. GMP 
regulations were developed by the US FDA and issued 
the United States CFR Chapter 21 in1978. The 
regulation was similar in concept to the Orange Guide, 
but enforceable by law whereas the UK guide as an 
advisory. US congress passed the Federal Ani-tempering 




In the 1980, US FDA began publishing series of 
guidance documents that have a major effect on our 
interpretation of current GMP (cGMP). A “Guide to 
Inspection of Computerized Systems in Drug 
Processing” was published in 1983 and “Guideline on 
General Principles of Process Validation” was published 
in 1987. March 1997, the US FDA issued 21 CFR Part 
11 which dealt with the use of electronic records and 
signatures. In 2000, US FDA introduced a guidance 
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ABSTRACT 
The holder of a manufacturing  authorization must manufacture medicinal products so as to ensure that they are fit for their 
intended use, comply with the requirements of the Marketing Authorization and do not place patients at risk due to 
inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management 
and requires the participation and commitment by staff in many different departments and at all levels within the company, 
by the company’s suppliers and by the distributors. To achieve the quality objective reliably there must be a 
comprehensively designed and correctly implemented system of Quality Assurance Incorporating Good Manufacturing 
Practice, and thus Quality Control and Quality Risk Management. It should be fully documented and its effectiveness 
monitored. All parts of the Quality Assurance systems should be adequately resourced with competent personnel, and 
suitable and sufficient premises, equipment and facilities. There are additional legal responsibilities for the holder of the 
manufacturing authorization and for the authorized person 
Keywords: Good Manufacturing Practice, Quality control, Quality assurance, authorized 
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GOOD MANUFACTURING PRACTICES (GMP) 
GUIDELINES- 
Many countries have legislated that pharmaceutical and 
medical device companies created their own GMP 
guidelines that correspond with their legislation. Basic 
concepts of GMP guidelines goal of safeguarding the 
health of the patient as well as producing good quality 
medicine, medical devices or active pharmaceutical 
products
4
. The formalization of GMP commenced in the 
1960s and their effect in over 100 countries ranging 
from Afghanistan to Zimbabwe. Examples of these 
include the following. 
a. Pharmaceutical Inspection Convention (PIC):- 
Guide to GMP for pharmaceutical products-Australia, 
Austria, Belgium, Canada, Italy, Latvia, Liechtenstein, 
Denmark, Finland, France, Hungary, Ireland, Malaysia, 
The Netherlands, Norway, Poland, Portugal, Romania, 
Singapore, Slovak Republic, Spain, Sweden, 
Switzerland, and the United Kingdom. 
b. Association of South-East Asia Nations (ASEAN):- 
General guidelines Brunei Darussalaam, Indonesia, Lao 
PDR, Malaysia,Cambodia, Myanmar, Philippines, 
Singapore, Thailand, and Vietnam. 
c. European Economic Community (EEC):- Guide to 
GMP for medicinal products Austria, Belgium, 
Denmark, Ireland, Italy, Luxembourg, the Netherlands, 
Finland, France, Germany, Greece, Portugal, Spain, 
Sweden, and the United Kingdom. In general, GMP has 
been issued guides to the achievement of consistent 
product quality, with interpretation and individual 
variations being accepted. GMP enforced in the United 
States by the US FDA, under Section 501(B) of the 1938 
Food, Drug, and Cosmetic Act .The regulations use the 
phrase "current good manufacturing practices” (c GMP) 
and it describes the guidelines.
5  
COMPONENTS OF GMP 
GMP requires that the manufacturing process is fully 
defined before being initiated and all the necessary 
facilities are provided. In practice, personnel must be 
adequately trained, suitable premises and equipment 
used, correct materials used, approved procedures 
adopted, suitable storage and transport facilities 
available, and appropriate records made
6





Components of Good Manufacturing Practice 
 
Indian schedule M for GMP and requirements of 
premises, plant and equipment for pharmaceutical 
products. Part I includes general requirements, 
Warehousing area, Production area, Quality control 
area, Personnel, Ancillary area, Health, clothing and 
sanitation of workers, Manufacturing operations and 
controls, Sanitation in the manufacturing  premises, Raw 
materials, Equipment, Documentation and Records, 
Labels and other printed materials, Quality assurance, 
Self inspection and quality audit, Quality control 
system, Specification, Master formula records, Packing 
records, Batch packaging records, Batch processing 
records, Standard operating procedures (SOPs) and 
records, Reference samples, Reprocessing and 
recoveries, Distribution records, Validation and process 
validation, Product recalls, Complaints and adverse 
reactions and Site-master file. Part I-A to part I-E 
mentions about the specific requirements for 
manufacture of different products and Part I-F mentions 
about the specific requirements of premises, plant and 
materials for manufacture of active pharmaceutical 
ingredients (bulk drugs). Part II describes the 




GOOD MANUFACTURING SERVICES –THE 
GENERAL/CURRENT STATE- 
QUALITY MANAGEMENT 
The holder of a manufacturing authorization must 
manufacture medicinal products so as to ensure that they 
are fit for their intended use ,comply with the 
requirements of the marketing authorization and do not 
place patients at risk due to inadequate safety, quality or 
efficacy .The attainment of this quality objective is the 
responsibility of senior management and requires the 
participation and commitment by staff in many different 
departments and at all levels within the company, by the 
company  suppliers and by the distributors
7 
In the 
pharmaceutical industry at large, quality
 
management is 
usually defined as the aspect of management function 
that determines and implements the “quality policy”, i.e. 
the overall intention and direction of an organization 
regarding quality, as formally expressed and authorized 
by top management 
8. 
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QUALITY ASSURANCE
 
Quality Assurance is a wide-ranging concept, which 
covers all matters, which individually or collectively 
influence the quality of a product. It is the sum total of 
the organized arrangements made with the objective of 
ensuring that medicinal products are of the quality 
required for their intended use. Quality Assurance 
therefore incorporates Good Manufacturing Practice 
plus other factors outside the scope of this Guide. The 
holder of a manufacturing authorization must 
manufacture medicinal products so as to ensure that they 
are fit for their intended use, comply with the 
requirements of the marketing authorization and do not 
place patients at risk due to inadequate safety, quality or 
efficacy. The attainment of this quality objective is the 
responsibility of senior management and requires the 
participation and commitment by staff in many different 
departments and within the company, by the company’ 
suppliers and by the distributors. QA is a wide ranging 
concept, which covers all matters, which individually or 
collectively influence the quality of a product. It is the 
sum total of the organized arrangements made with the 
objective of ensuring that pharmaceutical products are 
of the quality required for their intended use. QA, 
therefore, incorporates GMP and other factors such as 
product design and development
9.
 
The system of QA appropriate for the manufacture of 
pharmaceutical products should ensure that: 
a. Pharmaceutical products are designed and developed 
in a way that takes account of the requirements of GMP 
and other associated codes such as those of good 
laboratory practice (GLP) and good clinical practice 
(GCP). 
b. Production and control operations are clearly 
specified in a written form and GMP requirements are 
adopted. 
c. Arrangements are made for the manufacture, supply 
and use of the correct starting and packaging materials. 
d. All necessary controls on starting materials, 
intermediate products, and bulk products and other in-
process controls, calibrations, and validations are carried 
out. 
e. The finished product is correctly processed and 
checked, according to the defined procedures, 
pharmaceutical products are not sold or supplied before 
the authorized persons have certified that each 
production batch has been produced and controlled in 
accordance with the requirements of the marketing 
authorization and any other regulations relevant to the 
production, control and release of pharmaceutical 
products. 
f. Satisfactory arrangements exist to ensure, as far as 
possible, that the pharmaceutical products are stored by 
the manufacturer, distributed, and subsequently handled 
so that quality is maintained throughout their shelf-life; 
g. Deviations are reported, investigated and recorded. 
h. Regular evaluations of the quality of pharmaceutical 
products should be conducted with the objective of 
verifying the consistency of the process and ensuring its 
continuous improvement. 
GOOD MANUFACTURING PRACTICE FOR 
MEDICINAL PRODUCTS (GMP) 
Good Manufacturing Practice is that part of Quality 
Assurance which ensures that Medicinal products are 
consistently produced and controlled to the quality 
standards appropriate to their intended use and as 
required by the marketing authorization or product 
specification. Good Manufacturing Practice is concerned 
with both production and quality control. GMP is aimed 
primarily at diminishing the risks inherent in any 
pharmaceutical production
 10 
The basic requirements of 
GMP are that:  
• all manufacturing processes are clearly defined, 
systematically reviewed in the light of experience 
and shown to be capable of consistently 
manufacturing medicinal products of the required 
quality and complying with their specifications;  
•  critical steps of manufacturing processes and 
significant changes to the process are validated; 
• all necessary facilities for GMP are provided including: 
 a. appropriately qualified and trained personnel; 
 b. adequate premises and space; 
 c. suitable equipment and services;  
d. correct materials, containers and labels; 
 e. approved procedures and instructions; 
f.  suitable storage and transport; 
iv. Instructions and procedures are written in an 
instructional form in clear and unambiguous language, 
specifically applicable to the facilities provided; 
v- Operators are trained to carry out procedures 
correctly; 
vi. Records are made, manually and/or by recording 
instruments, during manufacture which demonstrate that 
all the steps required by the defined procedures and 
instructions were in fact taken and that the quantity and 
quality of the product was as expected
9. 
Any significant 
deviations are fully recorded and investigated; 
 vii. Records of manufacture including distribution 
which enable the complete history of a batch to be 
traced, are retained in a comprehensible and accessible 
form;  
viii. The distribution (wholesaling) of the products 
minimizes any risk to their quality;  
 ix. A system is available to recall any batch of product, 
from sale or supply;  
x. complaints about marketed products are examined, 
the causes of quality defects investigated and 
appropriate measures taken in respect of the defective 
products and to prevent re-occurrence
 11 
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Sanitation and Hygiene 
High level or sanitation and hygiene should be practiced 
in every aspect of manufacturing pharmaceutical 
products. The scope of sanitation and hygiene covers 
personnel, premises, equipment and apparatus, 
production materials and containers and anything that 
could become a source of contamination to the product[. 
Potential sources of contamination should be eliminated 




Every person entering the manufacturing areas should 
wear protective garments appropriate to the operations 
to be carried out.  
Personal hygiene procedures including requirement of 
using protective clothing should apply to all persons 
entering production areas, whether they are temporary or 
full-time employees or non-employees on company 
property, e.g. contractor’s employees, visitors, senior 
management and inspectors. 
To assure protection of the product from contaminations 
as well as the safety of the personnel, they should wear 
clean body-coverings appropriate to the duties they 
perform, including appropriate hair covering. Soiled 
uniforms and soiled cleaning cloths (if reusable) should 
be stored in separate closed containers until properly 
laundered. 
Detailed hygiene programmes should be established and 
adapted to the different needs within the manufacturing 
area. They should include procedures relating to the 
health, hygiene practices and clothing of personnel. 
These procedures should be understood and followed in 
a very strict way by every person whose duties take him 
into the production and control areas. Hygiene 
programmes should be promoted by management and 
widely discussed during training sessions. 
All personnel should receive medical examination upon 
recruitment. It must be the manufacturer's responsibility 
that there are instructions ensuring that health conditions 
that can be of relevance to the quality of products come 
to the manufacturer's knowledge. After the first medical 
examination, examinations should be carried out 
periodically for the work and personal health. Visual 
inspectors should also undergo periodic eye 
examination. 
The areas, surfaces, and equipment in and on which 
products are made must be kept clean. Dirt, and the 
microbes that it can harbor, must not get into or on 
products. Disinfectants can be inactivated by dirt. Dirt 
(particularly oily or greasy films and protein like matter) 
can also protect microorganisms against the action of 
disinfectants. So, before disinfection, it is important to 
first clean surfaces. Where gross amounts of dirt are 
present, it may be necessary to first remove most of it by 
scrubbing. Then surfaces may be cleaned by the 
application of a cleaning agent, followed by rising
13
. 
Validation   
Validation is defined as the establishing of documented 
evidence which provides a high degree of assurance that 
a planned process will consistently perform according to 
the intended specified outcomes. Validation studies 
should reinforce GMP and be conducted in accordance 
with defined procedures. Results and conclusions should 
be recorded. When any new manufacturing formula or 
method of preparation is adopted, steps should be taken 
to demonstrate its suitability for routine processing 
14
. 
Qualification of systems and equipment is therefore a 
part of process of validation. It is a requirement of food 
and drug, pharmaceutical regulating agencies like 
FDA’s guidelines. Since a wide variety of procedures, 
processes, and activities need to be validated, the field 
of validation is divided into a number of subsections 
including the following: 
• Equipment validation 
• Facilities validation 
• HVAC system validation 
• Cleaning validation 
• Process Validation 
• Analytical method validation 
• Computer system validation 
• Packaging validation 
Premises 
Premises and equipment must be located, designed, 
constructed, adapted and maintained to suit the 
operations to be carried out. Their layout and design 
must aim to minimise the risk of errors and permit 
effective cleaning and maintenance in order to avoid 
cross-contamination. 
Premises must be located, constructed, adapted, 
designed, and maintained to suit the operations to be 
carried out. The layout and design of premises must aim 
to minimize the risk of errors and permit effective 
cleaning and maintenance in order to avoid cross 
contamination, build-up of dust or dirt, and in general, 
any adverse effect on the quality of products
15
. The 
choices of materials of construction for manufacturing 




• a. Walls: Walls in manufacturing areas, packaging 
areas and corridors should be of plaster finish on 
high-quality concrete blocks or gypsum board. The 
finish should be smooth, usually with enamel or 
epoxy paint. They should be washable and able to 
resist repeated applications of cleaning and 
disinfecting agents. 
• b. Floors: Floor covering should be selected for 
durability as well as for clean ability and resistance 
to the chemicals with which it is likely to come into 
contact. Epoxy flooring provides a durable and 
readily cleanable surface. 
• c. Ceilings: Suspended ceilings may be provided in 
office areas, toilets, laboratories and cafeterias. 
They usually consist of lay-in acoustical panels of 
non brittle, non friable, non asbestos and non 
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combustible material. Manufacturing areas require a 
smooth finish, often of seamless plaster or gypsum 
board. All ceiling fixtures such as light fittings, air 
outlets and returns should be designed to assure 
ease of cleaning and to minimize the potential for 
accumulation of dust. 
• d. Services: In the building design, provisions must 
be made for drains, steam, electricity, water and 
other services to allow for ease of maintenance. 
Access should, ideally, be possible without 
disruption of activity within the actual rooms 
provided with the services. Doors and window-
frames should all have a hard, smooth, impervious 
finish, and should close tightly. Window and door 
frames should be fitted flush, at least on sides 
facing inward to processing areas. Doors, except 
emergency exits, should not open directly from 
production areas to the outside world. Any 
emergency exit doors should be kept shut and 





Manufacturing equipment should be capable of 
producing materials, products and intermediates that are 
intended and that conform to the required or specified 
quality characteristics. The equipment must be designed 
and built so that it is possible to clean it thoroughly. 
Surfaces that come into contact with products should 
have polished finishes, smooth with no recesses, 
crevices, difficult corners, uneven joints, dead-legs, 
projections, or rough welds to harbor contamination or 
make cleaning difficult. Equipment must also be capable 
of withstanding repeated, thorough cleaning. Traces of 
previous product, at levels that might be acceptable in 
other industries, are totally unacceptable in the 
manufacture of medicines. Between batches all 
manufacturing equipment must be thoroughly cleaned 




GMP is a production and testing practice that helps to 
ensure in built quality product. Many countries have 
legislated that pharmaceutical companies must follow 
GMP procedures, and have created their own GMP 
guidelines that correspond with their legislation. Basic 
concepts of all of these guidelines remain more or less 
similar to the ultimate goals of safeguarding the health 
of the patient as well as producing good quality 
medicines. 
Quality objective can be achieved only through careful 
planning and implementation of QA system and 
practical implementation of GMP. The effective 
implementation of GMP requires extensive care and 
knowledge about the different components of GMP that 
should be incorporated form the inception of the 
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